Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Acetazolamide

Preparation Calculator

USE IF: Altitude sickness prevention/treatment, glaucoma, idiopathic intracranial hypertension, selected metabolic alkalosis

AVOID IF: Severe renal impairment, hepatic disease, significant acidosis, sulfonamide hypersensitivity

Acetazolamide

Carbonic anhydrase inhibitor (acid–base, diuresis, ICP, and ocular effects)

AdultAltitudeGlaucomaIIHMetabolic alkalosisICUElectrolytesAcid–baseHigh-yield

Indication

Altitude sickness • Glaucoma • IIH • Metabolic alkalosis (selected)

At a glance

INDICATIONS (CORE USE)

- Altitude sickness (prevention and treatment) - Glaucoma - Idiopathic intracranial hypertension - Metabolic alkalosis (selected ICU use)

ADULT DOSE (STANDARD)

STANDARD: Indication-specific dosing (see product labeling and pathway) Onset: hours (context-dependent)

MAX DOSE

Indication- and context-dependent; titrate to response and safety (electrolytes, acid–base)

Route

PO • IV

PEDIATRIC DOSE

Protocol- and indication-specific; see labeling and specialty care

Do not miss

Must-not-miss safety points

Major warning

- Causes metabolic acidosis (mechanism-based) - Hypokalemia risk - Sulfonamide-related reactions - Renal stones - Avoid in severe hepatic disease (risk of encephalopathy)

Indications

INDICATION: Altitude sickness • Glaucoma • IIH • Metabolic alkalosis (selected)

Primary

  • Altitude sickness
  • Glaucoma
  • IIH

Secondary

  • Metabolic alkalosis (selected cases)

Dosing

STANDARD (ADULT PO)

Adult: indication-specific dosing (see labeling, neurology/ophthalmology/ICU pathways)

ADULT DOSE

STANDARD (ADULT): - Indication-specific dosing (altitude, glaucoma, IIH, metabolic alkalosis differ) - Use lowest effective exposure time for altitude/short-term strategies when appropriate

PEDIATRIC DOSE

Protocol- and indication-specific; see labeling and specialty care

MAX DOSE

Indication- and context-dependent; avoid empiric high-dose continuation without acid–base and electrolyte follow-up

Practical Note

- Start before ascent (altitude use) when that is the goal - Adjust based on response - Monitor electrolytes and acid–base status

Warnings

Clinical warnings

  • Metabolic acidosis
  • Hypokalemia
  • Paresthesia (common)
  • Renal stones
  • Hypersensitivity reactions

Adverse effects

  • Paresthesia
  • Fatigue
  • GI upset

Contraindications

  • Severe renal impairment
  • Hepatic disease (encephalopathy risk)
  • Sulfonamide hypersensitivity

Drug interactions

  • Other diuretics — additive electrolyte disturbances
  • Drugs whose effects depend on acid–base status — may be shifted (consult labeling / monitoring when relevant)

Special populations

Pediatrics

Protocol- and indication-specific; see labeling and specialty care

Pregnancy

Pregnancy /

Lactation

See product labeling and current obstetric references before use in pregnancy; confirm lactation risk if breastfeeding.

Renal impairment

Use caution; accumulation risk. Avoid or reduce exposure in severe impairment per labeling.

Hepatic impairment

Avoid (encephalopathy risk).

Elderly

Higher risk of electrolyte shifts, acidosis, and falls — more frequent lab/clinical follow-up when used.

Administration

- PO or IV - Adjust based on indication and monitoring plan

Monitoring

  • Monitor: - Electrolytes (K+, bicarbonate) - Acid–base status - Clinical response
  • Recheck: - During therapy and after dose changes - If targets not met or new symptoms → reassess dose and diagnosis; DO NOT continue blindly without electrolytes and acid–base follow-up
  • Hold if:
    - Significant acidosis
    - Hypokalemia (clinically relevant)
    - Clinical intolerance / emerging toxicity

Overdose / toxicity

Clinical Picture

Metabolic acidosis Electrolyte imbalance

Immediate Actions

Supportive care Correct electrolytes per presentation

Antidote

None specific

Decontamination

Acute ingestion: supportive care; poison center if large overdose or concern

Escalation

Severe acid–base derangement, arrhythmia, or renal compromise — escalate per acute care pathway

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Works by inducing mild metabolic acidosis
  • Useful in altitude acclimatization (when indicated)

Clinical

  • Not a strong diuretic for volume removal

Safety

  • Most common error = ignoring electrolyte and acid–base changes

Pharmacy Tool

Preparation Calculator

Acetazolamide 25 mg/mL oral suspension — methylcellulose system

suspension · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Renal excretion

Mechanism of action

- Carbonic anhydrase inhibition → bicarbonate loss

Common brand names

Saudi Arabia

Diamox, Acetazolamide

Global

(placeholder — verify local formulation)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Product labeling (acetazolamide: indications, contraindications, monitoring)
  • Local neuro-ophthalmology / ICU protocols (IIH, metabolic alkalosis)
  • Current altitude medicine references when applicable